newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

  • Phase 3 PEAK trial results for bezuclastinib in 2nd-line GIST patients expected in November 2025.
  • Pivotal APEX trial results for bezuclastinib in AdvSM patients expected in December 2025.
  • Breakthrough Therapy Designation granted for bezuclastinib in NonAdvSM patients.
  • New Drug Application (NDA) filing for NonAdvSM remains on track for year-end 2025.
  • Multiple bezuclastinib abstracts selected for the 67th Annual Meeting of the American Society of Hematology (ASH), including two oral presentations for SUMMIT NonAdvSM data.
  • Plan to showcase novel JAK2 V617F mutant-selective candidate at ASH 2025.
  • FDA alignment achieved on SUMMIT NDA submission plan for broad NonAdvSM patient population.
  • Positive top-line results reported from SUMMIT trial, achieving statistical significance across all primary & key secondary endpoints.
  • FDA cleared Investigational New Drug (IND) submission for CGT4255, a CNS-penetrant ErbB2 inhibitor, with Phase 1 trial initiation expected in November 2025.
  • JAK2 & pan-KRAS inhibitor programs remain on track for IND filings in 2026.
  • Company closed an upsized public offering in July generating $215.8 million in net proceeds.
  • Raised $39 million through targeted share sales via at-the-market facility.
  • Pro forma cash position of $430 million expected to fund operations through 2027.
  • Third quarter 2025 cash, cash equivalents, & marketable securities totaled $390.9 million.
  • Third quarter 2025 R&D expenses were $69.0 million, up from $63.6 million in the prior year period.
  • Third quarter 2025 G&A expenses were $14.4 million, up from $11.8 million in the prior year period.
  • Third quarter 2025 net loss was $80.9 million, compared to $70.6 million in the same period of 2024.
  • Approved inducement equity awards totaling 89,500 nonqualified options for five new employees under Nasdaq Listing Rule 5635(c)(4).